CELG: Message Board for Celgene Corporation | Forum profile

  Heard from three sources that a large institution with huge CELG position had to sell all healthcare - not really a CELG call - and shorts hopped on it. I beleive that selling is about done now and we should move higher soon. msg 140485

Originally published as JCO Early Release 10.1200/JCO.2009.24.0150 on September 21 2009   Journal of Clinical Oncology , Vol 27, No 32 (November 10), 2009: pp. e186-e187 ? 2009 American Society of Clinical Oncology. Michele Cavo , Lucia Pantani , Paola Tacchetti , Maria Caterina Pallotti , Annamaria Brioli , Alessandro Petrucci , Elena Zamagni , Patrizia Tosi "Ser?gnoli" Institute of Hematology, Bologna University School of...

After Hours Last: $ 53.05 After Hours High: $ 53.06 After Hours Volume: 79,802 After Hours Low: $ 52.7818 After Hours Time (ET) After Hours Price After Hours Share Volume 18:04  $ 53.05 76,769 16:15  $ 53.05 1,111 16:13  $ 53.06 530 16:12  $ 52.7818 900 16:05  $ 52.7818 200 16:04  $ 52.7818 292 msg ' +...

How far along are the trials? When will we see results? How promising is it? msg ' + item.replyToNumber + '

FWIW, this KOL was reticent about the Jak-2 as he believes that spleen reduction is a soft endpoint. He specifically commented that reduction in spleen without reduction in counts is not acceptable. He mentioned that in longer follow-up with Jak-2, they have not seen much improvement in counts.   BofA opined that pomalidomide+Jak-2 combination therapy might be useful at ASH2008:     Pomalidomide Improves Anemia in...

Pig, me too. Do you know how I can read a transcript of his comments on DNDN last night? tia. msg 140495

msg ' + item.replyToNumber + '

They'd be looking hard at acceleron ( biotech and bone growth ) if the VC's would take an offer- they will not be looking at celg-respectfully, IMHO. cm4 msg 140489

bought some today .... not expensive ....anyone in ?? msg ' + item.replyToNumber + '

it can't be stressed enough how much potential imids have as adjunctive agents in tx of many types of cancer - esp as the field moves further toward viewing these conditions as chronic diseases. maint therapy will likely be huge. msg 140494